Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]
You may also be interested in...
Actavis Divests In China But Looking For Acquisition; CEO Says Pfizer’s Established Products Division Possible
Actavis is pulling out of China because its business there is too small and complicated considering the investment of time and capital that could be better spent elsewhere But it could re-enter via a sizeable acquisition, such as Pfizer’s Established Products division.
Roche Global Head Of Partnering Sophie Kornowski-Bonnet On Finding Innovation In Asia (Part 2 of 2)
In an exclusive interview, Sophie Kornowski-Bonnet sits down with PharmAsia News to share her impressions of innovation in China and the company’s overall partnering strategy in China and emerging markets.
Roche Global Head Of Partnering Sophie Kornowski-Bonnet On Finding Innovation In Asia (Part 1 of 2)
Sophie Kornowski-Bonnet sits down with PharmAsia News to share her impressions of innovation in China and the company’s overall partnering strategy in China and emerging markets.